Literature DB >> 3119936

Therapy of mitochondrial disorders.

H Przyrembel1.   

Abstract

Mitochondrial disorders, namely defects of fatty acid oxidation, defects of pyruvate metabolism and defects of the respiratory chain are heterogenous in clinical picture and in response to therapeutic attempts. Defects of fatty acid metabolism are amenable to therapy by dietary means, carnitine substitution and in some cases with vitamins. Defects in pyruvate metabolism do not respond to therapy except in some special cases. Therapeutic attempts include dietary measures, vitamins as coenzyme precursors. Defects in the respiratory chain appear to respond to treatment only in exceptional cases. Evaluation of treatment effects appears to be singularly difficult. General measures that can be of benefit to different defects are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119936     DOI: 10.1007/bf01812853

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  36 in total

1.  Pyruvate carboxylase deficiency and lactic acidosis in a retarded child without Leigh's disease.

Authors:  B M Atkin; N R Buist; M F Utter; A B Leiter; B Q Banker
Journal:  Pediatr Res       Date:  1979-02       Impact factor: 3.756

2.  Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency.

Authors:  P F Bougnères; J M Saudubray; C Marsac; O Bernard; M Odièvre; J Girard
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

3.  31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.

Authors:  S Eleff; N G Kennaway; N R Buist; V M Darley-Usmar; R A Capaldi; W J Bank; B Chance
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

4.  Pyruvate dehydrogenase phosphatase deficiency: a cause of congenital chronic lactic acidosis in infancy.

Authors:  B H Robinson; W G Sherwood
Journal:  Pediatr Res       Date:  1975-12       Impact factor: 3.756

5.  Partial pyruvate decarboxylase deficiency with profound lactic acidosis and hyperammonemia: responses to dichloroacetate and benzoate.

Authors:  K McCormick; R M Viscardi; B Robinson; J Heininger
Journal:  Am J Med Genet       Date:  1985-10

6.  Recurrent myoglobinuria due to muscle carnitine palmityl transferase deficiency.

Authors:  M J Reza; N C Kar; C M Pearson; R A Kark
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

7.  Diagnostic and therapeutic implications of medium-chain acylcarnitines in the medium-chain acyl-coA dehydrogenase deficiency.

Authors:  C R Roe; D S Millington; D A Maltby; T P Bohan; S G Kahler; R A Chalmers
Journal:  Pediatr Res       Date:  1985-05       Impact factor: 3.756

8.  Treatment of Kearns-Sayre syndrome with coenzyme Q10.

Authors:  S Ogasahara; Y Nishikawa; S Yorifuji; F Soga; Y Nakamura; M Takahashi; S Hashimoto; N Kono; S Tarui
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

9.  A patient with pyruvate carboxylase deficiency in the liver: treatment with aspartic acid and thiamine.

Authors:  M G Baal; F J Gabreëls; W O Renier; F A Hommes; T H Gijsbers; K J Lamers; J C Kok
Journal:  Dev Med Child Neurol       Date:  1981-08       Impact factor: 5.449

10.  Familial recurrent rhabdomyolysis due to carnitine palmityl transferase deficiency.

Authors:  B M Patten; J M Wood; Y Harati; P Hefferan; R R Howell
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

View more
  15 in total

1.  Restoration of NADH-oxidation in complex I and complex III deficient fibroblasts by menadione.

Authors:  F A Wijburg; C J de Groot; N Feller; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 2.  Mitochondrial disorders and the kidney.

Authors:  P Niaudet
Journal:  Arch Dis Child       Date:  1998-04       Impact factor: 3.791

3.  Rapid isolation of muscle and heart mitochondria, the lability of oxidative phosphorylation and attempts to stabilize the process in vitro by taurine, carnitine and other compounds.

Authors:  H R Scholte; Y Yu; J D Ross; I I Oosterkamp; A M Boonman; H F Busch
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 4.  Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases.

Authors:  J A Morgan-Hughes; A H Schapira; J M Cooper; J B Clark
Journal:  J Bioenerg Biomembr       Date:  1988-06       Impact factor: 2.945

Review 5.  A scientific rationale for protective therapy in Parkinson's disease.

Authors:  C W Olanow
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy.

Authors:  B Barbiroli; R Medori; H J Tritschler; T Klopstock; P Seibel; H Reichmann; S Iotti; R Lodi; P Zaniol
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

7.  Epilepsy in a mitochondrial disorder.

Authors:  T Torbergsen; E Mathiesen; J Aasly
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

Review 8.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

9.  Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease.

Authors:  R Artuch; M A Vilaseca; M Pineda
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

10.  Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy.

Authors:  G Kurlemann; I Paetzke; H Möller; H Masur; G Schuierer; J Weglage; H G Koch
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.